Sawyer & Company Inc Sells 29,752 Shares of Amgen Inc. (NASDAQ:AMGN)

Sawyer & Company Inc decreased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 65.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,853 shares of the medical research company's stock after selling 29,752 shares during the period. Amgen makes up 1.8% of Sawyer & Company Inc's portfolio, making the stock its 17th largest position. Sawyer & Company Inc's holdings in Amgen were worth $4,507,000 at the end of the most recent quarter.

• Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Diversified Trust Co boosted its stake in Amgen by 76.8% in the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company's stock worth $10,857,000 after purchasing an additional 16,376 shares during the period. Provence Wealth Management Group boosted its stake in Amgen by 11.9% in the 4th quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company's stock worth $416,000 after purchasing an additional 154 shares during the period. Kinsale Capital Group Inc. boosted its stake in Amgen by 33.0% in the 4th quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company's stock worth $3,269,000 after purchasing an additional 2,814 shares during the period. Global Wealth Management Investment Advisory Inc. boosted its stake in Amgen by 2.4% in the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company's stock worth $1,363,000 after purchasing an additional 109 shares during the period. Finally, Traynor Capital Management Inc. boosted its stake in Amgen by 9.5% in the 4th quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company's stock worth $5,455,000 after purchasing an additional 1,650 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. TD Cowen reduced their target price on shares of Amgen from $370.00 to $360.00 and set a "buy" rating for the company in a research note on Wednesday, April 17th. Truist Financial restated a "buy" rating and set a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. StockNews.com upgraded shares of Amgen from a "hold" rating to a "buy" rating in a research note on Friday, May 3rd. Barclays upgraded shares of Amgen from an "underweight" rating to an "equal weight" rating and increased their price objective for the stock from $230.00 to $300.00 in a research note on Friday, May 3rd. Finally, Argus increased their price objective on shares of Amgen from $300.00 to $340.00 and gave the stock a "buy" rating in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Amgen has an average rating of "Moderate Buy" and an average price target of $307.35.

• Biotech Sector Nears Breakout: Will it Outperform in Q2?

Read Our Latest Analysis on AMGN

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the firm's stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares of the company's stock, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.69% of the company's stock.

Amgen Stock Performance

• 7 Stocks That Will Drive the Weight Loss Drugs Market

NASDAQ AMGN opened at $312.45 on Friday. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. The firm has a market capitalization of $167.61 billion, a price-to-earnings ratio of 44.64, a P/E/G ratio of 2.83 and a beta of 0.60. The firm's 50 day simple moving average is $301.56 and its 200 day simple moving average is $292.10. Amgen Inc. has a 1 year low of $218.44 and a 1 year high of $329.72.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating analysts' consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same quarter last year, the business posted $3.98 earnings per share. The company's quarterly revenue was up 22.0% on a year-over-year basis. As a group, research analysts expect that Amgen Inc. will post 19.47 earnings per share for the current fiscal year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Recommended Stories

• Five stocks we like better than Amgen
• How Can Investors Benefit From After-Hours Trading
• What's Behind Walgreens Stock Plunge: What Investors Can Do Next
• What is the Dogs of the Dow Strategy? Overview and Examples
• MarketBeat Week in Review – 6/24 - 6/28
• What is the S&P 500 and How It is Distinct from Other Indexes
• General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ The Election SHOCK Nobody Expected… (But You’ll See it Coming) (From Banyan Hill Publishing) (Ad)

Should you invest $1,000 in Amgen right now?

Before you consider Amgen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.

While Amgen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here